Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | NDAQ

Overview

Corporate Details

ISIN(s):: US4718712023 (+3 more)
LEI:
Country:: United States of America
Address:: 2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Website:: https://jaspertx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Coherus Oncology, Inc. Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.	United States of America	CHRS
COLLEGIUM PHARMACEUTICAL, INC Develops and commercializes abuse-deterrent medications for responsible chronic pain management.	United States of America	COLL
CollPlant Biotechnologies Ltd Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.	United States of America	CLGN
Compass Therapeutics, Inc. A clinical-stage oncology firm developing antibody therapies that engage the immune system.	United States of America	CMPX
Compugen Ltd. Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.	Israel	CGEN
COMPUGEN LTD AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.	United States of America	CGEN
Connect Biopharma Holdings Ltd Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.	United States of America	CNTB
Context Therapeutics Inc. Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.	United States of America	CNTX
Contineum Therapeutics, Inc. Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.	United States of America	CTNM
CORCEPT THERAPEUTICS INC Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.	United States of America	CORT